{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:10:26Z","timestamp":1784956226034,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008527","name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","doi-asserted-by":"publisher","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}],"id":[{"id":"10.13039\/100008527","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014042","name":"US Department of Defense Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0657"],"award-info":[{"award-number":["W81XWH-22-1-0657"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R1AI159379"],"award-info":[{"award-number":["R1AI159379"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["CPRIT RP200443"],"award-info":[{"award-number":["CPRIT RP200443"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018897","name":"Lions Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtcvs.2024.10.005","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T20:07:52Z","timestamp":1728590872000},"page":"1082-1095.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy"],"prefix":"10.1016","volume":"169","author":[{"given":"Sonali","family":"Mitra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Kuncheria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Wook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Seon","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Ranchod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheshwari","family":"Ramineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Taylor","family":"Ripley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn S.","family":"Groth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanda H.","family":"Blackmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan M.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-046X","authenticated-orcid":false,"given":"Hyun-Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtcvs.2024.10.005_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jtcvs.2024.10.005_bib2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtcvs.2024.10.005_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.jtcvs.2024.10.005_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtcvs.2024.10.005_bib7","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/j.jtho.2016.11.301","article-title":"OA13.02 Phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis","volume":"12","author":"Kindler","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"15","key":"10.1016\/j.jtcvs.2024.10.005_bib8","doi-asserted-by":"crossref","first-page":"8514","DOI":"10.1200\/JCO.2017.35.15_suppl.8514","article-title":"Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression","volume":"35","author":"Rivalland","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtcvs.2024.10.005_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10272","key":"10.1016\/j.jtcvs.2024.10.005_bib10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jtcvs.2024.10.005_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jtcvs.2024.10.005_bib12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-22-2566","article-title":"A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jtcvs.2024.10.005_bib13","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.3390\/diagnostics12123009","article-title":"Diagnostic and therapeutic challenges of malignant pleural mesothelioma","volume":"12","author":"Moro","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10.1016\/j.jtcvs.2024.10.005_bib14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.athoracsur.2020.10.031","article-title":"Prognostic role of programmed cell death 1 ligand 1 in resectable pleural mesothelioma","volume":"112","author":"Lee","year":"2021","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.jtcvs.2024.10.005_bib15","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.athoracsur.2021.08.054","article-title":"Inhibition of cyclin dependent kinase 4\/6 overcomes primary resistance to programmed cell death 1 blockade in malignant mesothelioma","volume":"114","author":"Jang","year":"2022","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.jtcvs.2024.10.005_bib16","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.athoracsur.2017.06.042","article-title":"Soluble mesothelin-related peptides to monitor recurrence after resection of pleural mesothelioma","volume":"104","author":"Burt","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"10.1016\/j.jtcvs.2024.10.005_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98575","article-title":"Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma","volume":"3","author":"Lee","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtcvs.2024.10.005_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2021.01.011","article-title":"Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial","volume":"154","author":"Katz","year":"2021","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.jtcvs.2024.10.005_bib19","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.21037\/tlcr-20-673","article-title":"Immunotherapy in malignant pleural mesothelioma: a review of literature data","volume":"10","author":"Menis","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"9","key":"10.1016\/j.jtcvs.2024.10.005_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003032","article-title":"Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy","volume":"9","author":"Harber","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jtcvs.2024.10.005_bib21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41591-019-0380-z","article-title":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","volume":"25","author":"Rothwell","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtcvs.2024.10.005_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.jtcvs.2024.10.005_bib23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/annonc\/mdz046","article-title":"Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium","volume":"30","author":"Li","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jtcvs.2024.10.005_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease: latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtcvs.2024.10.005_bib25","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jtcvs.2024.10.005_bib26","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2019.08.012","volume":"14","author":"Gill","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.jtcvs.2024.10.005_bib27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.jtcvs.2024.10.005_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2015.36","article-title":"The use of Luminex assays to measure cytokines","volume":"135","author":"Khalifian","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.jtcvs.2024.10.005_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jtcvs.2024.10.005_bib30","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"issue":"43","key":"10.1016\/j.jtcvs.2024.10.005_bib32","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.jtcvs.2024.10.005_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2023.09.008","article-title":"PL03. 10 MARS 2: a multicentre randomised trial comparing (extended) pleurectomy decortication versus no radical surgery for mesothelioma","volume":"18","author":"Lim","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jtcvs.2024.10.005_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jtcvs.2024.10.005_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2006.08.010","article-title":"What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update","volume":"38","author":"Ord\u00f3\u00f1ez","year":"2007","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.jtcvs.2024.10.005_bib36","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Schneider","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.jtcvs.2024.10.005_bib37","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jtho.2018.04.032","article-title":"A phase I trial of surgical resection and intraoperative hyperthermic cisplatin and gemcitabine for pleural mesothelioma","volume":"13","author":"Burt","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jtcvs.2024.10.005_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12964-023-01438-0","article-title":"Emerging mechanisms of the unfolded protein response in therapeutic resistance: from chemotherapy to immunotherapy","volume":"22","author":"He","year":"2024","journal-title":"Cell Commun Signal"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522324009140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522324009140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:39:46Z","timestamp":1778654386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022522324009140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0022522324009140"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2024.10.005","relation":{},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2024.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Association for Thoracic Surgery","name":"copyright","label":"Copyright"}]}}